Egetis Therapeutics AB (publ)

Research Egetis Therapeutics AB (publ) (EGTX) on Bullrun: market cap SEK 2.60B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEGTX
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 2.60B
• Financial periodFY2024
• RevenueSEK 46.10M
• Revenue growth-20.0%
• Net income-SEK 343.60M
• Free cash flow-SEK 227.90M
• Gross margin74.8%

Valuation Snapshot

latest market cap is SEK 2.60B.

About Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency.

Frequently asked questions

What is Egetis Therapeutics AB (publ)'s market cap?

Egetis Therapeutics AB (publ)'s market capitalization is SEK 2.60B.

What does Egetis Therapeutics AB (publ) do?

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.